📖 🔥New online from our group at @UTMDAnderson on ultra-precision oncology in #lungcancer 👉 Analysis from over 22,000 #EGFR-mutant tumor samples identified #PACC mutations in 12% of cases (A) 👉 While classical and #Ex20 mutations more commonly occur as single mutations, PACC mutations are more frequently (66%) observed as compound mutations (B). 👉 PACC/PACC and PACC/classical-like compound mutations function biologically similar to single PACC mutations, NOT classical mutations (C) 👉 Compound PACC mutations demonstrate greater sensitivity to EGFR TKIs than single PACC mutations (D) ⚡ 💡 Largest #EGFR mutation landscape in a Western population. ⚡ 💡 #Compound EGFR PACC Eare biologically analogous to #single PACC. ⚡ 💡 Important insights for drug development of next-generation EGFR TKIs.

🎀 💗Strong team work! BH-30643 represents a next-generation #EGFR #TKI that is potentially 10x more potent than osimertinib, strong CNS penetrance, and able to overcome on-target EGFR resistance! @Exon20Group @EGFRResisters @UTMDAnderson @mollylisc @geoff_oxnard @jjeancui

Kicking off #ASCO26 by celebrating the Giants of Cancer Care induction ceremony! 🎀Congratulations to Dr. Wakelee @HwakeleeMD for Thoracic Malignancy 🎀Congratulations to Dr. Kopetz @skopetz for GI Maligancy @UTMDAnderson 🎀Congratulations to Dr. William Wierda for Leukemia 💐💐💐With friends @drgandara @JoelNealMD @riess_md

At #ASCO26, the @UTMDAnderson Thoracic Medical Oncology Department will deliver an incredible 9 oral presentations💐💐💐 highlighting advances across ##EGFR, #HER2, #KRAS, #KEAP1/STK11, #SCLC, IO, #peri-operative, all lung cancer subgroups. For perspective, thoracic medical oncologists from China have 16 oral presentations. 👩‍⚕️🧑‍⚕️ 👩‍🔬🧑‍🔬Our entire MDA Thoracic team @FSkoulidis @NIVokes @LaurenByersMD @lungoncdoc Drs. Heymach, Cascone, Zhang, @mvnegrao @YYElamin @AnneTsao2 are deeply proud and excited 😀to help shape the future of lung cancer research and patient care alongside outstanding collaborators and industry partners.

Dr. Stephen Liu @StephenVLiu gave the insightful vision on how #AI will impact our clinic, including patient care, physician wellness, clinical research and drug development. @StephenVLiu at #RomeLung26 Thank you @FedericoCappuz1 @BRicciutiMD for organizing this fantastic #lung #summit

Strongly support my @UTMDAnderson colleague Dr. Hussein Tawbi @HTawbi_MD for #SITC Director election ❤️💐 👉Hussein is an internally renowned #physicianscientist immune-oncology leader who has helped redefine what immunotherapy can achieve in some of the most challenging clinical settings. 👉His leadership of the CheckMate 204 study established the role of nivolumab ipilimumab in melanoma brain metastases, a historically underserved population, 👉He led RELATIVITY-047 which enabled the approval of nivolumab relatlimab, introducing LAG-3 as a new checkpoint target. His voice and compassion, grounded in patient care and scientific rigor, would be an outstanding addition to the #SITC Board as we navigate the next era of immunotherapy innovation. 🚀

Strongly support Dr. Zhen Su @MyOncology , my friend, colleague, and mentor for SITC Director election. 💪❤️ 👉When he served as the global oncology leader at #MerckKGaA/#EMDSerono, he translated complex immune biology to approvals, then becaome impactful therapies for patients. He has multiple global approvals across agents such as #avelumab, #tepotinib, #erbitux and others. 👉Now as the CEO of #Marengo, he is a true architect with vision, taking first-in-class T-cell agonist programs from platform stage into human studies and secured strong partnerships. 👉Zhen has been a long-standing contributor to the #immuno-oncology community, including leadership roles within #SITC. His vision of bringing early discovery to global commercialization will continue shaping the development of next generation immunotherapies. 🚀

Appreciate @StephenVLiu and @CharuAggarwalMD organizing a fantastic US Focus Meeting Lung Cancer. I discussed 1L EGFR-mut NSCLC landscape evolution with friends and colleagues @riess_md @JuliaRotow @JustinGainor @ShirishGadgeel @BalazsHalmosMD. Nashville is a charming city with such fun characters.

😊 🩷 Nice to see friends and colleagues in the #lungcancer community from different continents at #ELCC26. @caliraf @Alfdoc2 @HHorinouchi @MartinReck2 @Tony_Calles @DoctorJSpicer @fred_hirsch @bensolomon1 @NReguart @BalazsHalmosMD @BrendonStilesMD @mollylisc @karenkellymd @ThomasW35874311 @NadalErnest @DrSanjayPopat 😊 🩷 Safe travels ✈️ 💐💐💐Grateful for the wonderful organization between @IASLC and @esmo for an impactful and fun #ELCC26.

We discussed innovations in ADCs to overcome topo-payload ADC resistance. 🔥Novel payloads include dual-cytotoxic, radioligands, immune stimulators or engagers, oligonucleotides (siRNA), degraders, and small molecule inhibitors. 🤣 Yes, "Any-Drug-Conjugates (ADC)" ❤️💡

Honored to be delivering two educational lectures at 🔜 #ELCC26 @myESMO🇩🇰 in Copenhagen. 📍 March 26. 👉Beyond traditional ADCs: Advances in targeting, conjugation, payload design, and emerging modalities 📍 March 28 👉Mechanisms of resistance: Lessons from EGFR-mutant and ALK-rearranged NSCLC 💐Grateful to the conference chairs @DrSanjayPopat @APassaroMD for your excellent work on organizing #ELCC26. 💗Looking forward to great discussions and connecting with global colleagues @HHorinouchi @ThomasW35874311 @Alfdoc2 @caliraf @tnewsomdavis @YYElamin @lungoncdoc

Please (re)watch the powerful Special Speech delivered by Dr. Ross Camidge @DRCamidge at #TTLC26 @IASLC An internationally renowned thoracic oncologist, Dr. Camidge shared something profoundly personal: his own diagnosis and treatment journey with stage IV #EGFR-mutant #NSCLC. His reflections were thoughtful and deeply human. It is a reminder that before we are physicians or patients, we are human beings: vulnerable yet resilient. Please: ❤️ Act with urgency. ❤️ Treat with respect and gentleness. ❤️ Move forward with courage and hope. @ShirishGadgeel @lungoncdoc @KarenReckampMD @TejasPatilMD

❤️ ❤️ So happy and proud to wrap up a successful #TTLC26 @IASLC 💐🎊 👉 This year, we set new records: 🥇 🔥 the highest attendance, 🥇 🔥 the greatest number of submitted abstracts, and 🥇 🔥 unprecedented sponsorship support. 👉 This year, we hosted two extraordinary keynote speakers: my mentor Dr. John Heymach @MDAndersonNews and his mentor Dr. Bruce E. Johnson. Seeing multiple generations of thoracic oncology leadership on one stage was a powerful reminder that progress in our field is built on mentorship, collaboration, and legacy. Let it continue. ❤️ ❤️ Special appreciation to my dear co-chairs @ShirishGadgeel @KarenReckampMD and Dr. Paul Bunn, and outstanding @IASLC staff, especially Kelly Heemsbergen, for being consistently knowledgeable, responsive, and supportive behind the scenes. 👉 See you all again at hashtag #TTLC27

#TTLC26 @IASLC @YYElamin @MDAndersonNews Dr. Yasir Elamin discussed the landscape for 1L #EGFR mutant #lungcancer until now, and offered insights to the near future. 👉Intensification works for PFS and OS 👉More intensification strategies are coming.

#TTLC26 @IASLC Day 1. Opening Keynote by Dr. John Heymach, focusing on "heterogeneity" in Thoracic Oncology @lungoncdoc @ReckampK @ShirishGadgeel @MDAndersonNews 👉 EGFR classical vs. PACC vs. Ex20ins 👉 EGFR Ex20ins - near vs. far loop 👉 KRAS - co-mut STK11 KEAP1 vs. TP53 👉 SCLC - transcriptional profiling